Translational studies have identified transcriptomic definitions of SCLC subgroups (9), highlighting that the subgroup of patients classified as “inflamed” over-expresses innate immune pathway genes, such as the STING pathway genes CCL5 and CXCL10, that sustain the inflamed microenvironment primed for immunotherapy response. The gene discussed is STING1; the disease is small cell lung carcinoma.